Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intra-cellular Thera74, Inc. (ITCI) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intra-cellular Thera74, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1567514.
Total stock buying since 2013: $37,228,078.
Total stock sales since 2013: $221,630,438.
Total stock option exercises since 2013: $38,819,239.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 0 | $0 | 194,413 | $447,104 |
| 2024 | 0 | $0 | 1,090,880 | $78,720,145 | 1,102,290 | $17,403,636 |
| 2023 | 0 | $0 | 628,333 | $33,154,112 | 448,741 | $6,152,215 |
| 2022 | 0 | $0 | 869,163 | $47,246,424 | 608,335 | $4,920,844 |
| 2021 | 0 | $0 | 709,405 | $29,141,374 | 680,947 | $7,036,339 |
| 2020 | 70,500 | $2,054,880 | 540,983 | $14,573,504 | 495,984 | $1,791,815 |
| 2019 | 880,000 | $9,151,370 | 186,620 | $2,343,330 | 228,332 | $320,240 |
| 2018 | 0 | $0 | 138,314 | $2,559,736 | 105,779 | $93,750 |
| 2017 | 786,490 | $12,188,751 | 34,800 | $549,800 | 142,377 | $289,030 |
| 2016 | 297,000 | $4,651,389 | 9,375 | $142,921 | 30,507 | $40,843 |
| 2015 | 250,000 | $6,000,000 | 234,400 | $11,512,388 | 203,750 | $238,423 |
| 2014 | 208,531 | $3,181,688 | 119,542 | $1,686,704 | 162,500 | $81,250 |
| 2013 | 0 | $0 | 0 | $0 | 12,500 | $3,750 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-17 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 53,968 | 12.73 | 687,012 |
| 2022-12-13 | Mates Sharon (Chairman, President & CEO) | Sale | 33,083 | 55.00 | 1,819,565 |
| 2022-12-01 | Halstead Michael (EVP and General Counsel) | Sale | 100,000 | 53.71 | 5,371,000 |
| 2022-12-01 | Halstead Michael (EVP and General Counsel) | Option Ex | 100,000 | 15.47 | 1,547,000 |
| 2022-09-21 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 65,164 | 45.63 | 2,973,759 |
| 2022-09-21 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 65,164 | 15.47 | 1,008,087 |
| 2022-08-11 | Van Nostrand Robert L (Director) | Sale | 30,000 | 56.98 | 1,709,250 |
| 2022-08-11 | Van Nostrand Robert L (Director) | Option Ex | 30,000 | 12.75 | 382,500 |
| 2022-08-11 | Marcus Joel S (Director) | Sale | 10,000 | 59.22 | 592,200 |
| 2022-05-12 | Marcus Joel S (Director) | Sale | 10,000 | 55.00 | 550,000 |
| 2022-04-08 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 86,348 | 64.37 | 5,558,220 |
| 2022-04-08 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 86,348 | 12.73 | 1,099,210 |
| 2022-03-18 | Riggs Rory B (Director) | Sale | 20,637 | 60.99 | 1,258,629 |
| 2022-03-17 | Riggs Rory B (Director) | Sale | 141,499 | 60.20 | 8,518,381 |
| 2022-03-16 | Riggs Rory B (Director) | Sale | 64,534 | 59.12 | 3,815,572 |
| 2022-03-09 | Mates Sharon (Chairman, President & CEO) | Option Ex | 38,925 | 2.84 | 110,547 |
| 2022-03-08 | Marcus Joel S (Director) | Sale | 15,000 | 52.57 | 788,550 |
| 2022-03-07 | Marcus Joel S (Director) | Sale | 5,000 | 54.52 | 272,600 |
| 2022-03-04 | Durgam Suresh K. (Chief Medical Officer) | Sale | 3,860 | 55.52 | 214,307 |
| 2022-03-02 | Durgam Suresh K. (Chief Medical Officer) | Sale | 4,177 | 56.98 | 238,005 |
| 2022-02-24 | Durgam Suresh K. (Chief Medical Officer) | Sale | 4,046 | 52.17 | 211,067 |
| 2022-02-24 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 7,906 | 52.10 | 411,902 |
| 2022-02-24 | Mates Sharon (Chairman, President & CEO) | Sale | 22,589 | 51.63 | 1,166,202 |
| 2022-02-24 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 7,454 | 51.65 | 385,021 |
| 2022-02-24 | Halstead Michael (EVP and General Counsel) | Sale | 7,906 | 52.00 | 411,112 |
| 2022-02-23 | Durgam Suresh K. (Chief Medical Officer) | Option Ex | 7,906 | .00 | 0 |
| 2022-02-23 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,906 | .00 | 0 |
| 2022-02-23 | Mates Sharon (Chairman, President & CEO) | Option Ex | 22,589 | .00 | 0 |
| 2022-02-23 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 7,454 | .00 | 0 |
| 2022-02-23 | Halstead Michael (EVP and General Counsel) | Option Ex | 7,906 | .00 | 0 |
| 2022-02-22 | Durgam Suresh K. (Chief Medical Officer) | Sale | 4,177 | 55.16 | 230,424 |
| 2022-02-22 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 11,139 | 55.22 | 615,095 |
| 2022-02-22 | Mates Sharon (Chairman, President & CEO) | Sale | 27,847 | 55.35 | 1,541,470 |
| 2022-02-22 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 10,443 | 55.35 | 578,072 |
| 2022-02-22 | Halstead Michael (EVP and General Counsel) | Sale | 11,139 | 55.34 | 616,376 |
| 2022-02-18 | Durgam Suresh K. (Chief Medical Officer) | Option Ex | 8,354 | .00 | 0 |
| 2022-02-18 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 11,139 | .00 | 0 |
| 2022-02-18 | Mates Sharon (Chairman, President & CEO) | Option Ex | 27,847 | .00 | 0 |
| 2022-02-18 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 10,443 | .00 | 0 |
| 2022-02-18 | Halstead Michael (EVP and General Counsel) | Option Ex | 11,139 | .00 | 0 |
| 2022-01-18 | Durgam Suresh K. (Chief Medical Officer) | Sale | 6,223 | 42.03 | 261,552 |
| 2022-01-10 | Durgam Suresh K. (Chief Medical Officer) | Sale | 6,870 | 40.65 | 279,244 |
| 2022-01-10 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 20,948 | 40.88 | 856,291 |
| 2022-01-10 | Mates Sharon (Chairman, President & CEO) | Sale | 41,896 | 40.87 | 1,712,415 |
| 2022-01-10 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 19,639 | 40.82 | 801,605 |
| 2022-01-10 | Halstead Michael (EVP and General Counsel) | Sale | 19,639 | 40.89 | 803,038 |
| 2022-01-08 | Durgam Suresh K. (Chief Medical Officer) | Option Ex | 13,093 | .00 | 0 |
| 2022-01-08 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 20,948 | .00 | 0 |
| 2022-01-08 | Mates Sharon (Chairman, President & CEO) | Option Ex | 41,896 | .00 | 0 |
| 2022-01-08 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 19,639 | .00 | 0 |
| 2022-01-08 | Halstead Michael (EVP and General Counsel) | Option Ex | 19,639 | .00 | 0 |
| 2021-12-21 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 175,000 | 46.41 | 8,121,749 |
| 2021-12-21 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 175,000 | 16.72 | 2,926,000 |
| 2021-12-21 | Halstead Michael (EVP and General Counsel) | Sale | 176,863 | 46.79 | 8,275,066 |
| 2021-12-21 | Halstead Michael (EVP and General Counsel) | Option Ex | 176,863 | 15.72 | 2,780,286 |
| 2021-10-18 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 13,448 | 40.15 | 539,869 |
| 2021-10-18 | Mates Sharon (Chairman, President & CEO) | Sale | 8,192 | 40.00 | 327,680 |
| 2021-10-15 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 13,448 | .00 | 0 |
| 2021-10-15 | Mates Sharon (Chairman, President & CEO) | Sale | 40,392 | 40.00 | 1,615,680 |
| 2021-10-15 | Mates Sharon (Chairman, President & CEO) | Option Ex | 1,075 | 2.84 | 3,053 |
| 2021-10-14 | Mates Sharon (Chairman, President & CEO) | Sale | 1,416 | 40.00 | 56,640 |
| 2021-08-23 | Mates Sharon (Chairman, President & CEO) | Option Ex | 10,000 | 2.84 | 28,400 |
| 2021-06-14 | Marcus Joel S (Director) | Sale | 18,289 | 42.27 | 773,076 |
| 2021-06-14 | Marcus Joel S (Director) | Option Ex | 20,000 | 38.35 | 767,000 |
| 2021-05-27 | Riggs Rory B (Director) | Option Ex | 13,767 | .00 | 0 |
| 2021-05-24 | Alafi Christopher D (Director) | Sale | 26,575 | 40.47 | 1,075,490 |
| 2021-05-21 | Alafi Christopher D (Director) | Sale | 1,100 | 40.00 | 44,000 |
| 2021-03-02 | Marcus Joel S (Director) | Sale | 15,250 | 34.93 | 532,682 |
| 2021-03-02 | Marcus Joel S (Director) | Option Ex | 20,000 | 26.58 | 531,600 |
| 2021-02-19 | Durgam Suresh K. (Chief Medical Officer) | Sale | 2,734 | 39.08 | 106,831 |
| 2021-02-19 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 5,184 | 39.08 | 202,590 |
| 2021-02-19 | Mates Sharon (Chairman, President & CEO) | Sale | 27,847 | 39.09 | 1,088,539 |
| 2021-02-19 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 10,442 | 39.09 | 408,177 |
| 2021-02-19 | Halstead Michael (EVP and General Counsel) | Sale | 11,139 | 39.09 | 435,479 |
| 2021-02-18 | Durgam Suresh K. (Chief Medical Officer) | Option Ex | 8,354 | .00 | 0 |
| 2021-02-18 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 11,139 | .00 | 0 |
| 2021-02-18 | Mates Sharon (Chairman, President & CEO) | Option Ex | 27,847 | .00 | 0 |
| 2021-02-18 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 10,442 | .00 | 0 |
| 2021-02-18 | Halstead Michael (EVP and General Counsel) | Option Ex | 11,139 | .00 | 0 |
| 2021-01-11 | Durgam Suresh K. (Chief Medical Officer) | Sale | 4,367 | 31.86 | 139,154 |
| 2021-01-11 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 9,684 | 32.02 | 310,081 |
| 2021-01-11 | Mates Sharon (Chairman, President & CEO) | Sale | 41,896 | 31.85 | 1,334,387 |
| 2021-01-11 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 19,638 | 31.86 | 625,568 |
| 2021-01-11 | Halstead Michael (EVP and General Counsel) | Sale | 19,638 | 31.86 | 625,666 |
| 2021-01-08 | Durgam Suresh K. (Chief Medical Officer) | Option Ex | 13,092 | .00 | 0 |
| 2021-01-08 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 20,948 | .00 | 0 |
| 2021-01-08 | Mates Sharon (Chairman, President & CEO) | Option Ex | 41,896 | .00 | 0 |
| 2021-01-08 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 19,638 | .00 | 0 |
| 2021-01-08 | Halstead Michael (EVP and General Counsel) | Option Ex | 19,638 | .00 | 0 |
| 2021-01-04 | Mates Sharon (Chairman, President & CEO) | Sale | 48,341 | 31.16 | 1,506,547 |
| 2021-01-04 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 15,810 | 31.17 | 492,797 |
| 2021-01-04 | Halstead Michael (EVP and General Counsel) | Sale | 16,160 | 31.16 | 503,626 |
| 2021-01-03 | Mates Sharon (Chairman, President & CEO) | Option Ex | 34,341 | .00 | 0 |
| 2021-01-03 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 16,160 | .00 | 0 |
| 2021-01-03 | Halstead Michael (EVP and General Counsel) | Option Ex | 16,160 | .00 | 0 |
| 2020-12-18 | Mates Sharon (Chairman, President & CEO) | Option Ex | 34,000 | 2.74 | 93,160 |
| 2020-11-17 | Halstead Michael (EVP and General Counsel) | Sale | 79,425 | 27.77 | 2,206,029 |
| 2020-11-17 | Halstead Michael (EVP and General Counsel) | Option Ex | 75,000 | 13.86 | 1,039,500 |
| 2020-11-11 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 28,034 | 25.41 | 712,343 |
| 2020-11-11 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 20,000 | 3.05 | 61,000 |
| 2020-11-10 | Mates Sharon (Chairman, President & CEO) | Sale | 50,000 | 26.45 | 1,322,500 |
| 2020-11-04 | Mates Sharon (Chairman, President & CEO) | Sale | 50,000 | 25.00 | 1,250,000 |
| 2020-10-16 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 6,792 | 26.80 | 182,025 |
| 2020-10-15 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 13,448 | .00 | 0 |
| 2020-09-14 | Alafi Christopher D (Director) | Buy | 49,500 | 29.60 | 1,465,200 |
| 2020-09-11 | Alafi Christopher D (Director) | Buy | 21,000 | 28.08 | 589,680 |
| 2020-09-09 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 41,983 | 31.14 | 1,307,350 |
| 2020-09-09 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 26,983 | 12.73 | 343,493 |
| 2020-06-25 | Marcus Joel S (Director) | Option Ex | 14,005 | .00 | 0 |
| 2020-06-25 | Riggs Rory B (Director) | Option Ex | 14,005 | .00 | 0 |
| 2020-05-14 | Marcus Joel S (Director) | Sale | 9,602 | 20.04 | 192,424 |
| 2020-05-13 | Marcus Joel S (Director) | Sale | 7,297 | 20.63 | 150,537 |
| 2020-05-11 | Lerner Richard A (Director) | Sale | 3,500 | 20.50 | 71,750 |
| 2020-05-11 | Lerner Richard A (Director) | Option Ex | 25,000 | 2.74 | 68,500 |
| 2020-05-11 | Marcus Joel S (Director) | Sale | 50,000 | 19.95 | 997,500 |
| 2020-01-09 | Satlin Andrew (EVP and Chief Medical Officer) | Sale | 11,573 | 26.16 | 302,749 |
| 2020-01-09 | Mates Sharon (Chairman, President & CEO) | Sale | 41,895 | 26.16 | 1,095,973 |
| 2020-01-09 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 19,638 | 26.16 | 513,730 |
| 2020-01-09 | Halstead Michael (EVP and General Counsel) | Sale | 19,638 | 26.16 | 513,730 |
| 2020-01-08 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 20,947 | .00 | 0 |
| 2020-01-08 | Satlin Andrew (EVP and Chief Medical Officer) | Option Ex | 22,911 | .00 | 0 |
| 2020-01-08 | Mates Sharon (Chairman, President & CEO) | Option Ex | 101,895 | 1.83 | 186,162 |
| 2020-01-08 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 19,638 | .00 | 0 |
| 2020-01-08 | Halstead Michael (EVP and General Counsel) | Option Ex | 19,638 | .00 | 0 |
| 2020-01-06 | Mates Sharon (Chairman, President & CEO) | Sale | 45,598 | 30.09 | 1,371,815 |
| 2020-01-06 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 21,458 | 30.10 | 645,885 |
| 2020-01-06 | Halstead Michael (EVP and General Counsel) | Sale | 21,458 | 30.13 | 646,529 |
| 2020-01-03 | Mates Sharon (Chairman, President & CEO) | Option Ex | 45,598 | .00 | 0 |
| 2020-01-03 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 21,458 | .00 | 0 |
| 2020-01-03 | Halstead Michael (EVP and General Counsel) | Option Ex | 21,458 | .00 | 0 |
| 2020-01-02 | Mates Sharon (Chairman, President & CEO) | Sale | 17,478 | 32.96 | 576,022 |
| 2020-01-02 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 7,807 | 32.97 | 257,396 |
| 2020-01-02 | Halstead Michael (EVP and General Counsel) | Sale | 7,807 | 32.95 | 257,217 |
| 2019-12-31 | Mates Sharon (Chairman, President & CEO) | Option Ex | 6,000 | 2.74 | 16,440 |
| 2019-12-23 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 15,032 | 25.50 | 383,316 |
| 2019-12-23 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 9,600 | 2.74 | 26,304 |
| 2019-10-16 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 6,774 | 8.25 | 55,885 |
| 2019-10-15 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 13,448 | .00 | 0 |
| 2019-09-10 | Alafi Christopher D (Director) | Buy | 485,000 | 10.04 | 4,868,430 |
| 2019-08-30 | Alafi Christopher D (Director) | Buy | 125,000 | 8.52 | 1,065,250 |
| 2019-06-18 | Marcus Joel S (Director) | Option Ex | 14,189 | .00 | 0 |
| 2019-06-18 | Riggs Rory B | Option Ex | 14,189 | .00 | 0 |
| 2019-06-12 | Alafi Christopher D (Director) | Buy | 170,000 | 11.54 | 1,961,290 |
| 2019-05-29 | Marcus Joel S (Director) | Option Ex | 20,000 | 12.45 | 249,000 |
| 2019-05-14 | Alafi Christopher D (Director) | Buy | 100,000 | 12.56 | 1,256,400 |
| 2019-02-27 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 1,000 | 15.00 | 15,000 |
| 2019-02-27 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 10,400 | 2.74 | 28,496 |
| 2019-01-07 | Mates Sharon (Chairman, President & CEO) | Sale | 6,604 | 12.43 | 82,087 |
| 2019-01-07 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 3,108 | 12.42 | 38,601 |
| 2019-01-07 | Vanover Kimberly E. (SVP, Early Stage Clinical Dev.) | Sale | 592 | 12.29 | 7,275 |
Insider trading activities including stock purchases, stock sales, and option exercises of ITCI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intra-cellular Thera74, Inc. (symbol ITCI, CIK number 1567514) see the Securities and Exchange Commission (SEC) website.